248 results on '"Drake, Justin M."'
Search Results
2. ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems
3. Targeting RET Kinase in Neuroendocrine Prostate Cancer
4. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
5. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway
6. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer
7. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade
8. Supplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
9. Supplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
10. Data from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
11. Supplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
12. Supplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
13. Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection
14. Abstract A020: Deciphering DNA damage repair in ATM mutant prostate cancers
15. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma
16. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer
17. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
18. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis
19. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.
20. Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
21. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
22. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells
23. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets
24. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
25. Supplementary Figure 6 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
26. Supplementary Figure 3 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
27. Supplementary Figure 5 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
28. Supplementary Figure 4 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
29. Supplementary Table 1 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
30. Supplementary Figure 1 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
31. Data from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
32. Supplementary Figure 2 from Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
33. Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells
34. Abstract 2405: Delineating molecular vulnerabilities of ATM mutant prostate cancers
35. Abstract 191: CTC-derived organoids from liver and pancreatic cancer patients for personalized therapy
36. Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
37. Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
38. Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer
39. Supplementary Figure 1 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
40. Supplementary Figure 7 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
41. Supplementary Figure 5 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
42. Supplementary Figure 6 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
43. Supplementary Figure 2 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
44. Supplementary Figure 3 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
45. Supplementary Figure 4 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
46. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer
47. Integrating phosphoproteomics into the clinical management of prostate cancer
48. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
49. Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer
50. PIP5K1α inhibition as a therapeutic strategy for prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.